Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2016

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2016
Published Aug 24, 2016
68 pages — Published Aug 24, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2016, provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Stargardt Disease)
- The report reviews pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Juvenile Macular Degeneration (Stargardt Disease) therapeutics and enlists all their major and minor projects
- The report assesses Juvenile Macular Degeneration (Stargardt Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease)


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease)
- Identify potential new clients or partners in the target demographic
- Develop strategic

  
Source:
Document ID
GMDHC8396IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Juvenile Macular Degeneration (Stargardt Disease) Overview71
Therapeutics Development82
  Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease) Overview81
  Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease) Comparative Analysis91
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics under Development by Companies101
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics under Investigation by Universities/Institutes111
Juvenile Macular Degeneration (Stargardt Disease) Pipeline Products Glance122
  Clinical Stage Products121
  Early Stage Products131
Juvenile Macular Degeneration (Stargardt Disease) Products under Development by Companies141
Juvenile Macular Degeneration (Stargardt Disease) Products under Investigation by Universities/Institutes151
Juvenile Macular Degeneration (Stargardt Disease) Companies Involved in Therapeutics Development166
  Acucela Inc.161
  Alkeus Pharmaceuticals, Inc.171
  Astellas Pharma Inc.181
  Copernicus Therapeutics, Inc.191
  Iris Pharma201
  Sanofi211
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Assessment229
  Assessment by Monotherapy Products221
  Assessment by Target232
  Assessment by Mechanism of Action252
  Assessment by Route of Administration272
  Assessment by Molecule Type292
Drug Profiles3125
  ALK-001 Drug Profile311
  echothiophate iodide Drug Profile321
  emixustat hydrochloride Drug Profile334
  Gene Therapy 1 to Activate ABCA4 for Stargardt Disease Drug Profile371
  Gene Therapy to Activate ABCA4 for Stargardt Disease Drug Profile381
  MA09-hRPE Drug Profile3910
  Oligonucleotides to Activate ABCA4 for Stargardt Disease Drug Profile491
  ramiprilat Drug Profile501
  SAR-422459 Drug Profile512
  soraprazan Drug Profile531
  Stem Cell Therapy for Ophthalmic Disorders Drug Profile541
  VM-200 Drug Profile551
Juvenile Macular Degeneration (Stargardt Disease) Dormant Projects561
Juvenile Macular Degeneration (Stargardt Disease) Product Development Milestones5710
  Featured News &Press Releases571
    May 26, 2015: Ocata Therapeutics Receives Three New U.S. Patents for its RPE Therapy for Macular Degenerative Diseases571
    May 04, 2015: European Medicines Agency Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease571
    Mar 31, 2015: Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies581
    Oct 15, 2014: ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration581
    Sep 25, 2014: Advanced Cell Technology Announces Final Patient Treated in Stargardt s Macular Degeneration Phase 1 Trial in the United Kingdom591
    Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials601
    May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells611
    Apr 23, 2013: ACT Initiates Higher-Dosage Patient Treatment In European Phase I Study For Macular Degeneration611
    Apr 15, 2013: ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt s Macular Dystrophy611
    Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy621
    Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells631
    Jan 08, 2013: Advanced Cell Technology Achieves Clinical Milestone641
    Dec 17, 2012: ACT Completes Higher-Dosage Cohort In European Clinical Trial For Stargardt's Macular Dystrophy Using Retinal Pigment Epithelial Cells641
    Nov 28, 2012: ACT Completes Higher-Dosage Cohort In Both US Clinical Trials Using Retinal Pigment Epithelial Cells651
    Nov 08, 2012: Advanced Cell Technology Announces Interim Data From Three Ongoing Macular Degeneration Trials652
Appendix672
  Methodology671
  Coverage671
  Secondary Research671
  Primary Research671
  Expert Panel Validation671
  Contact Us671
  Disclaimer681

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2016" Aug 24, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Juvenile-Macular-Degeneration-Stargardt-Disease-Pipeline-Review-H2-2016-2088-16437>
  
APA:
Global Markets Direct - Market Research. (2016). Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2016 Aug 24, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Juvenile-Macular-Degeneration-Stargardt-Disease-Pipeline-Review-H2-2016-2088-16437>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.